Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/obc

Journal Name

ARTICLE



A Direct and Vicinal Functionalization of the 1-Methyl-2-quinolone Framework: 4-Alkoxylation and 3-Chlorination

Feiyue Hao,^a Haruyasu Asahara^{*a,b} and Nagatoshi Nishiwaki^{*a,b}

Accepted 00th January 20xx DOI: 10.1039/x0xx00000x

Received 00th January 20xx,

www.rsc.org/

Bis(functionalization), 4-alkoxylation and 3-chlorination, of the 1-methyl-2-quinolone framework were achieved under mild conditions by the sequential treatment of 3-nitrated 1-methyl-2-quinolones with sodium alkoxide and *N*-chlorosuccinimide. Moreover, a succinimide group instead of an alkoxy group was introduced at the 4-position, affording a masked form of the 4-amino-3-chloro-2-quinolone derivative. Furthermore, the prepared vicinally functionalized quinolones thus obtained were subjected to Suzuki-Miyaura coupling reaction, arylating the 3-position.

Introduction

The 1-methyl-2-quinolone (MeQone) framework is present in more than 300 quinoline alkaloids exhibiting versatile biological activities.¹ In addition to the synthesis of naturally occurring MeQones, the synthesis of unnatural MeQone derivatives has attracted much attention as it allows access to new biologically active compounds,² among which MeQone derivatives possessing a hydroxy/an alkoxy group at the 4position are important.³ Moreover, the enol partial structure is a useful scaffold for the modification of the MeQone framework.³ Despite their usefulness, 4-alkoxylated **MeQones** have not been prepared by the direct alkoxylation of MeQone because of the inertness caused by the aromaticity.⁴ Instead, an alkoxy group has been introduced into MeQone by the alkylation⁵ of 4-hydroxylated **MeQone**s constructed from anthranilic acid derivatives⁶ or *N*-methylanilines.⁷ However, it is difficult to modify the MeQone framework because of the low availability of the corresponding starting materials. Hence, the development of a direct alkoxylation method for the MeQone framework is in high demand.

We have shown that 1-methyl-3,6,8-trinitro-2-quinolone (**TNQ**) is highly reactive among **MeQones** to form either a C–C or C–N bond at the 4-position regioselectively or to undergo cycloaddition reaction readily.⁸⁻¹¹ Inspired by these results, we envisioned that direct C–O bond formation at the 4-position of **MeQone** would be possible by the treatment of 3-nitrated

^bResearch Center for Material Science and Engineering, Kochi University of Technology, Miyanokuchi, Tosayamada, Kami, Kochi 782-8502, Japan

Email: nishiwaki.nagatoshi@kochi-tech.ac.jp; Fax: +81 887 57 2520; Tel: +81 887 57 2517

MeQones including **TNQ** with an alkoxide ion. In this case, it is necessary to trap the anionic adduct intermediate by an electrophile because a heteronucleophile is easily eliminated even though it adds to **TNQ**.¹⁰ We focused on the halogenation because **MeQones** bearing both an alkoxy and a halo group serve as important precursors for various types of compounds.^{12,13}

Halogenation at the 3-position of the **MeQone** framework is usually achieved by the treatment of 4-hydroxylated **MeQone** with halogenating agents such as thionyl chloride,¹⁴ *N*-bromosuccinimide (NBS),¹⁵ bromine,¹⁶ *N*-iodosuccinimide (NIS)¹³ and iodine.¹⁷ However, only a few examples of the halogenation of 4-alkoxylated **MeQone** have been reported,^{12,13} and there is no report on 3-chlorination. Hence, direct bis(functionalization), 4-alkoxylation and 3-halogenation, using 3-nitrated **MeQone**s would afford a new synthetic intermediate for the construction of a new compound library of **MeQone** derivatives.

Results and discussion

To evaluate the potential for vicinal functionalization, TNQ was chosen as a model substrate. When TNQ was treated with sodium methoxide in methanol at room temperature, the color of the solution immediately became reddish yellow, and a yellow solid precipitated in the reaction mixture (Scheme 1). In the ¹H NMR of solid **1a** collected by filtration, two new singlet signals appeared at 3.15 and 5.96 ppm instead of the disappearance of the singlet at 9.26 ppm assigned to the proton at the 4-position of TNQ. This spectral change indicated that a methoxide ion was added to the 4-position of TNQ, as confirmed by the correlations of the methoxy group with H-4 and H-5 in the ${}^{1}H-{}^{1}H$ NOESY 2D spectrum. Furthermore, a signal for C-4 was observed at 73 ppm in the ¹³C NMR spectrum, indicating the change from the sp² carbon to the sp³ carbon. Although 1a was confirmed to have a methoxylated structure, TNQ was reproduced by the treatment of 1a with

^aSchool of Environmental Science and Engineering, Kochi University of Technology, Miyanokuchi, Tosayamada, Kami, Kochi 782-8502, Japan

Electronic Supplementary Information (ESI) available: Copies of $^1\mathrm{H}$ and $^{13}\mathrm{C}$ NMR spectra data for all new products.

[[]details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

ARTICLE

hydrochloric acid. Moreover, **1a** was highly soluble into water. Hence, product **1a** exists in an anionic form stabilized by the _____ adjacent nitro and carbonyl groups.

Sodium ethoxide caused a similar reaction, affording **1b** quantitatively. On the other hand, precipitates were not observed during the reaction in other alcohols; however, the formation of **1** was confirmed by the ¹H NMR spectrum of the – residue after the removal of the solvent.



Next, adduct **1a** was reacted with *N*-chlorosuccinimide (NCS) in dichloromethane, affording the 3-chlorinated product, 4-methoxy-3-chloro-1-methyl-6,8-dinitro-2-quinolone (**MeO-Cl-DNQ**), in 45% yield (Table 1, entry 1). The structure was confirmed from the following spectral data. In the MS spectrum, the molecular ion peaks (313 and 315) were observed in a 3:1 intensity ratio, indicating that a chlorine atom was introduced. Although the H-4 signal disappeared, the signal of the methoxy group remained in the ¹H NMR. Furthermore, the signal assigned to C-4 shifted from 73 to 160 ppm in the ¹³C NMR spectrum.

Polar solvents were suitable for this reaction; the yield was increased up to 85% when acetonitrile was used (entries 2–5). The methoxy group of **1a** did not exchange with an ethoxy group even though the reaction was carried out in ethanol (entry 3). In each case, 4-imidated product **2** was also obtained and became the major product when DMF was used as the solvent (entry 4). Under these optimized reaction conditions, **EtO-CI-DNQ** was obtained similarly as a yellow solid in 73% yield along with **2** in 21% yield.



		Yield/%		
Entry	Solvent	MeO-CI-DNQ	2	
1	CH_2CI_2	45	trace	
2	THF	83	11	
3	EtOH	76	7	
4	DMF	35	40	
5	MeCN	85	10	



		Yield/%	
Entry	R	RO-CI-DNQ	2
1	Bu	42	10
2	<i>i</i> -Bu	46	0
3	<i>i</i> -Pr	45	0
4	PhCH ₂ CH ₂ (Phet)	55	0
5	Allyl	51	0
6	Propargyl (Prg)	29	20

In the cases of other chloroalkoxylation, a one-pot method was used to simplify the experimental operations (Table 2, entries 1–6). Namely, after a solution of **TNQ** and sodium alkoxide in alcohol was stirred at room temperature for 4 h, a solution of NCS in acetonitrile was added, and the resulting mixture was stirred at room temperature for further 6 h. Then, the solvent was removed, and the residue was purified to afford **RO-Cl-DNQ** in a moderate yield. Moreover, an allyloxy or a propargyloxy group was introduced at the 4-position (entries 5 and 6), facilitating further chemical transformations.

To expand the substrate scope of this protocol, sodium salt **1a** was reacted with other *N*-halosuccinimides. Bromination using NBS afforded the corresponding **MeO-Br-DNQ** in 62% yield (Scheme 2). In this reaction, 4-methoxylated trinitroquinolone **3** was also obtained in 27% yield, probably because of the higher leaving ability of bromide than chloride. Indeed, product **3** was obtained without detectable **MeO-I-DNQ** in the reaction of **1a** with NIS. On the other hand, neither the alkoxylated product nor halogenated product was formed in the reactions using Br₂, ICl, and I₂ as the halogenating agent.

Journal Name

Journal Name ARTICLE



In our previous work, we clarified the high reactivity of **TNQ** was caused by the steric repulsion between the 1-methyl and 8-nitro groups, distorting the **MeQone** framework to reduce the aromaticity.⁹ To the contrary, such steric repulsion was not crucial for this reaction because of the high nucleophilicity of the alkoxide anion. 1,8-Dimethyl-3,6-dinitro-2-quinolone (4) and 1-methyl-3,6-dinitro-2-quinolone (5) underwent the 4-alkoxylation efficiently under the same conditions to afford adducts 6 and 7 without observation of the considerable decrease of the yield, respectively (Scheme 3). Subsequent chlorination of 6 and 7 also proceeded upon treatment with NCS leading to 8 and 9 in high yields, respectively.



On the other hand, when 1,8-dimethyl-3,5-dinitro-2-quinolone **12** was employed as the substrate, *cine*-substituted product **13** was obtained without any detectable adduct intermediate **14**. In this reaction, addition of a methoxide surely occurred to afford **14**, however, it is not stable because of steric repulsion with *peri*-substituent. In order to release this repulsion, proton transfer to the 3-position is considered to occur, which undergoes the elimination of nitrite ion accompanied by aromatization to afford *cine*-substituted product **13** (Scheme 4).



To elucidate the mechanism of the reaction, several experiments were carried out. This reaction should proceed via 3,4dihydroquinoline intermediate **15** from which nitrous acid is eliminated, affording **RO-X-DNQ**. Although all other attempts to isolate **15** were unsuccessful, the reaction of **1a** with NCS in CH₂Cl₂ in a short reaction time (0.5 h) successfully produced **15** in 45% yield. Dihydroquinoline **15** remained unreacted when a solution of **15** in acetonitrile was stirred at room temperature for 6 h. In contrast, the same solution in the presence of triethylamine furnished **MeO-CI-DNQ** quantitatively (Scheme 5). In this reaction, sodium succinimide (Na-SI) may have acted as a base. Indeed, the addition of Na-SI facilitated the elimination of nitrous acid from **15**, affording **MeO-CI-DNQ** quantitatively without any detectable imidation product **2** (Scheme 5).



Scheme 5 Elimination of nitrous acid from intermediate 15

Next, some experiments were carried out to obtain insights into the imidation. When **MeO-CI-DNQ** was reacted with equimolar Na-SI, no reaction occurred, indicating that product **2** was not formed from **MeO-CI-DNQ**. On the other hand, chloroimidation occurred by the treatment of **TNQ** with NCS and Na-SI (Scheme 6). Hence, imidation proceeds competitively with the alkoxylation of **TNQ**.



Based on the abovementioned results, a plausible mechanism of

ARTICLE

this transformation is illustrated in Scheme 7. The reaction is initiated with the nucleophilic addition of an alkoxide at the 4position of TNQ, furnishing 1a as a relatively stable sodium salt. The reaction of 1a with NCS facilitates chlorination at the 3-position by nucleophilic substitution, affording 3,4-dihydroquinoline 15. Then a nitrous acid molecule is eliminated, leading to the formation of bis(functionalized) product MeO-CI-DNQ. In some cases, TNQ was regenerated under equilibrium and then underwent nucleophilic addition with Na-SI followed by chlorination and rearomatization, affording imidated product 2.





In the chlorination step of 1a, NCS approaches from the trans direction to avoid the steric hindrance of the methoxy group. Hence, nitrous acid is preferentially eliminated over hydrogen chloride in the next rearomatization step because a hydrogen atom and a nitro group are antiperiplanar.¹⁸

As shown in Scheme 6, TNQ also underwent the chloroimidation, affording product 2 in a moderate yield. This can be regarded as a masked form of aminated quinolone, NH2-CI-DNQ. Indeed, NH2-CI-DNQ was isolated in 51% yield by the hydrazinolysis of compound 2 (Scheme 8). Aminated MeQones are usually synthesized by chemical conversion from hydroxy derivatives via chloro derivatives.¹⁹ As an alternative approach, a ring is also constructed on an aniline derivative.²⁰ However, no direct amination method for the **MeQone** framework has been reported, except for our report.¹¹

Hence, this imidation is a useful method for the direct aminochlorination of the MeQone framework.



Finally, to illustrate the synthetic potential of our protocol, compound MeO-CI-DNQ was subjected to Suzuki-Miyaura coupling reaction²¹ because **MeQones** possessing an alkoxy group and an aryl group at the vicinal positions serve as $\alpha 4$ integrin inhibitors.²² When MeO-CI-DNQ was reacted with 4-methylphenylboronic acid in the presence of a Pd catalyst, arylated product 16 was successfully obtained in a moderate yield (Scheme 9).



Conclusions

In conclusion, we have developed a direct and vicinal functionalization of the MeQone framework under mild conditions by the treatment of **TNQ** with sodium alkoxides followed by treatment with NCS. This procedure facilitates the regioselective haloalkoxylation readily with simple experimental manipulations. Moreover, chloroimidation proceeded, leading to 4-imidated product 2 which is an equivalent of aminated MeQone. The prepared vicinally functionalized MeQones will serve as key synthetic intermediates for versatile MeQones. As one example, the palladium-catalyzed arylation at the 3-position was demonstrated. Hence, this protocol will be used as a powerful tool for constructing a compound library of MeQones.

Experimental

Experimental Section

The melting points were determined on a Yanaco micro-meltingpoints apparatus, and are uncorrected. All the reagents and solvents were commercially available and used as received. The ¹H NMR spectra were measured on a Bruker Ascend-400 at 400 MHz with tetramethylsilane as an internal standard. The ¹³C NMR spectra were measured on a Bruker Ascend-400 at 100 MHz, and assignments of ¹³C NMR spectra were performed by DEPT experiments. The IR spectra were recorded on a JASCO FT/IR-4200 spectrometer. The mass spectra and high-resolution mass spectra were measured on an AB SCIEX Triple TOF[™] 4600. The gas

Journal Name ARTICLE

chromatography mass spectrum was measured on a JEOL JMS-Q1050GC Ultra Quad GC/MS.

Preparation of 3-nitrated quinolones

1-Methyl-2-quinolone was prepared from quinoline by methylation with Me_2SO_4 followed by oxidation with $K_3[Fe(CN)_6]$ under alkaline conditions. Nitration of 1-methyl-2-quinolone with fuming HNO₃ afforded **TNQ** in 86% total yield.²³

Other nitroquinolones **4**, **5** and **12** were also prepared in a similar way. Dinitroquinolones were obtained when milder reaction conditions were used in the nitration step.⁹

General procedure for synthesis of 1a and 1b

To a solution of **TNQ** (500 mg, 1.70 mmol) in MeOH (5.5 mL), was added a solution of NaOMe (119 mg, 2.21mmol) in MeOH (0.6 mL), and the resultant mixture was stirred at room temperature for 4 h. The precipitated solid was collected by filtration to afford **1a** (474 mg, 1.36 mmol, 81%) as a yellow powder. The reaction of **TNQ** with NaOEt was performed to prepare **1b** in a similar way.

(6,8-Dinitro-4-methoxy-1-methyl-2-oxo-1,2,3,4-

tetrahydroquinolin-3-yl)sodium (1a). Yellow powder (474 mg, 1.36 mmol, 81%); mp 218–220 °C (dec.); ¹H NMR (DMSO-*d*₆, 400 MHz) δ = 2.97 (s, 3H), 3.15 (s, 3H), 5.96 (s, 1H), 8.55 (d, *J* = 2.4 Hz, 1H), 8.60 (d, *J* = 2.4 Hz, 1H); ¹³C NMR (DMSO-*d*₆, 100 MHz): δ = 33.6 (CH₃), 53.9 (CH₃), 73.0 (CH), 106.6 (C), 121.1 (CH), 126.9 (CH), 129.8 (C), 137.2 (C), 139.0 (C), 139.2 (C), 159.9 (C); IR: v (cm⁻¹) 1634, 1531, 1520, 1335; HRMS (ESI): Calcd for C₁₁H₁₀N₄NaO₈ [(M+H)⁺]: 349.0391, found 349.0386.

(6,8-Dinitro-4-ethoxy-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-

3-yl)sodium (1b). Yellow powder (615 mg, 1.70 mmol, quant.); mp 213–215 °C (dec.); ¹H NMR (DMSO- d_6 , 400 MHz) δ = 1.02 (t, J = 6.8 Hz, 3H), 2.97 (s, 3H), 3.47 (q, J = 6.8 Hz, 2H), 6.03 (s, 1H), 8.53 (d, J = 2.8 Hz, 1H), 8.59 (d, J = 2.8 Hz, 1H); ¹³C NMR (DMSO- d_6 , 100 MHz) δ = 15.4 (CH₃), 33.6 (CH₃), 61.7 (CH₂), 71.7 (CH), 107.1 (C), 121.0 (CH), 126.7 (CH), 130.5 (C), 137.2 (C), 138.9 (C), 139.2 (C), 160.0 (C); IR: v (cm⁻¹) 1633, 1537, 1531, 1334; HRMS (ESI) Calcd for C₁₂H₁₂N₄NaO₈ [(M+H)⁺]: 363.0547, found 363.0541.

General procedure for synthesis of MeO-Cl-DNQ and EtO-Cl-DNQ

To a solution of **1a** (70 mg, 0.20 mmol) in MeCN (1.0 mL), NCS (32 mg, 0.24 mmol) was added, and the resultant mixture was stirred at room temperature for 6 h. Then, the solvent was evaporated to afford a reaction mixture as a yellow residue, from which **MeO-CI-DNQ** was isolated through SiO₂ column chromatography (eluted with CH_2Cl_2 /hexane = 4/1), respectively. **EtO-CI-DNQ** was prepared in a similar way.

3-Chloro-4-methoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one

 $\label{eq:cl-DNQ} \end{tabular} \end{tabu$

3-Chloro-4-ethoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one (EtO-Cl-DNQ). Yellow powder (46 mg, 0.14 mmol, 73%); $R_{\rm f}$ = 0.21 (CH₂Cl₂/hexane = 4/1); mp 161–163 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 1.59 (t, *J* = 6.8 Hz, 3H), 3.54 (s, 3H), 4.62 (q, *J* = 6.8 Hz, 2H), 8.72 (d, *J* = 2.8 Hz, 1H), 8.99 (d, *J* = 2.8 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ

= 15.7 (CH₃), 35.7 (CH₃), 71.2 (CH₂), 116.4 (C), 121.7 (C), 122.3 (CH), 122.7 (CH), 135.2 (C), 139.0 (C), 140.8 (C), 157.2 (C), 160.0 (C); IR: v (cm⁻¹) 1682, 1537, 1531, 1352, 1335; HRMS (ESI) Calcd for $C_{12}H_{10}CIN_3O_6[(M-H)]$: 326.0185, found 326.0201.

General procedure for one-pot method of synthesis of RO-CI-DNQ To a solution of Na (7 mg, 0.31 mmol) in alcohol (0.3 mL), TNQ (70 mg, 0.24 mmol) was added, and the resultant mixture was stirred at room temperature for 4 h. Then, a solution of NCS (38 mg, 0.29 mmol) in MeCN (1.0 mL) was added, and the resultant mixture was stirred at room temperature for further 6 h. Then, the solvent was evaporated to afford a reaction mixture as a yellow residue, from which **RO-CI-DNQ** was isolated through SiO₂ column chromatography (eluted with CH₂Cl₂/hexane = 4/1).

4-Butoxy-3-chloro-1-methyl-6,8-dinitroquinolin-2(1*H***)-one** (**BuO-Cl-DNQ**). Yellow powder (35 mg, 0.10 mmol, 42%); $R_{\rm f}$ = 0.25 (CH₂Cl₂/hexane = 4/1); mp 135–136 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 1.05 (t, *J* = 7.6 Hz, 3H), 1.59 (tq, *J* = 7.6, 7.6 Hz, 2H), 1.94 (tt, *J* = 6.8, 6.8 Hz, 2H), 3.54 (s, 3H), 4.53 (t, *J* = 6.8 Hz, 2H), 8.72 (d, *J* = 2.8 Hz, 1H), 8.98 (d, *J* = 2.8 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ = 13.7 (CH₃), 19.0 (CH₂), 32.1 (CH₂), 35.7 (CH₃), 75.1 (CH₂), 116.3 (C), 121.6 (C), 122.3 (CH), 122.7 (CH), 135.2 (C), 139.0 (C), 140.8 (C), 157.4 (C), 160.1 (C); IR: v (cm⁻¹) 1682, 1537, 1531, 1354; HRMS (ESI) Calcd for C₁₄H₁₅ClN₃O₆ [(M+H)⁺]: 356.0644, found 356.0639.

3-Chloro-4-isobutoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one (*i*-**BuO-Cl-DNQ**). Yellow powder (38 mg, 0.11 mmol, 46%); $R_f = 0.30$ (CH₂Cl₂/hexane = 4/1); mp 146–147 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 1.16 (d, J = 6.4 Hz, 6H), 2.28 (m, 1H), 3.54 (s, 3H), 4.29 (d, J = 6.4 Hz, 2H), 8.72 (d, J = 2.4 Hz, 1H), 9.01 (d, J = 2.4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ = 19.0 (CH₃), 29.4 (CH), 35.6 (CH₃), 81.3 (CH₂), 116.2 (C), 121.5 (C), 122.2 (CH), 122.6 (CH), 135.3 (C), 139.0 (C), 140.8 (C), 157.4 (C), 160.1 (C); IR: v (cm⁻¹) 1674, 1537,1531, 1354; HRMS (ESI) Calcd for C₁₄H₁₅ClN₃O₆ [(M+H)⁺]: 356.0644, found 356.0639.

3-Chloro-4-isopropoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one (*i*-**PrO-Cl-DNQ).** Yellow powder (37 mg, 0.11 mmol, 45%); $R_f = 0.25$ (CH₂Cl₂/hexane = 4/1); mp 168–170 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 1.50 (d, J = 6.0 Hz, 6H), 3.55 (s, 3H), 5.28 (septet, J = 6.0 Hz, 1H), 8.72 (d, J = 2.4 Hz, 1H), 9.02 (d, J = 2.4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ = 22.7 (CH₃), 35.7 (CH₃), 78.7 (CH), 116.9 (C), 122.2 (CH), 122.7 (C), 123.0 (CH), 135.2 (C), 139.0 (C), 140.7 (C), 156.5 (C), 160.0 (C); IR: v (cm⁻¹) 1678, 1537, 1531, 1346; HRMS (ESI) Calcd for C₁₃H₁₁ClN₃O₆ [(M-H)]: 340.0342, found 340.0348.

3-Chloro-6,8-dinitro-1-methyl-4-(2-phenylethoxy)quinolin-2(1H)-

one (PhetO-CI-DNQ). Yellow powder (53 mg, 0.13 mmol, 55%); R_f = 0.22 (CH₂Cl₂/hexane = 4/1); mp 142–144 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 3.23 (t, *J* = 6.4 Hz, 2H), 3.51 (s, 3H), 4.82 (t, *J* = 6.4 Hz, 2H), 7.21–7.34 (m, 5H), 8.65 (d, *J* = 2.8 Hz, 1H), 8.73 (d, *J* = 2.8 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz): δ = 35.7 (CH₃), 36.5 (CH₂), 75.3 (CH₂), 115.7 (C), 121.4 (CH), 122.2 (C), 122.8 (CH), 127.1 (CH), 128.8 (CH), 128.9 (CH), 135.1 (C), 136.6(C), 138.9 (C), 140.7 (C), 157.0 (C), 160.0 (C); IR: v (cm⁻¹) 1681, 1537, 1531, 1352, 1301; HRMS (ESI) Calcd for C₁₈H₁₃ClN₃O₆ [(M-H)]: 402.0498, found 402.0512.

3-Chloro-1-methyl-6,8-dinitro-4-(prop-2-enyloxy)quinolin-2(1H)one (AllylO-CI-DNQ). Yellow powder (41 mg, 0.12 mmol, 51%); $R_f = 0.22$ (CH₂Cl₂/hexane = 4/1); mp 130–131 °C; ¹H NMR (CDCl₃, 400 MHz) $\delta = 3.54$ (s, 3H), 5.04 (dt, J = 6.0, 1.2 Hz, 2H), 5.43 (dd, J = 1.2, 10.4 Hz, 1H), 5.52 (ddt, J = 16.8, 1.2, 1.2 Hz, 1H), 6.13 (ddt, J = 10.4,

Journal Name

ARTICLE

16.8, 6.0 Hz, 1H), 8.72 (d, J = 2.8 Hz, 1H), 9.00 (d, J = 2.8 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) $\delta = 35.7$ (CH₃), 75.4 (CH₂), 117.1 (C), 121.4 (CH₂), 121.8 (C), 122.3 (CH), 122.9 (CH), 131.2 (CH), 135.2 (C), 139.0 (C), 140.8 (C), 157.0 (C), 159.9 (C); IR: v (cm⁻¹) 1674, 1536, 1530, 1350; HRMS (ESI) Calcd for C₁₃H₉CIN₃O₆ [(M-H)⁻]: 338.0185, found 338.0178.

3-Chloro-1-methyl-4-(prop-2-ynyloxy)-6,8-dinitroquinolin-2(1H)-

one (PrgO-Cl-DNQ). Yellow powder (23 mg, 0.07 mmol, 29%); R_f = 0.20 (CH₂Cl₂/hexane = 4/1); mp 153–155 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 2.61 (t, *J* = 2.4 Hz, 1H), 3.56 (s, 3H), 5.23 (d, *J* = 2.4 Hz, 2H), 8.74 (d, *J* = 2.8 Hz, 1H), 9.12 (d, *J* = 2.8 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ = 35.8 (CH₃), 61.5 (CH₂), 76.4 (CH), 78.7 (C), 118.4 (C), 121.9 (C), 122.5 (CH), 123.6 (CH), 135.0 (C), 139.0 (C), 140.8 (C), 156.4 (C), 159.7 (C); IR: v (cm⁻¹) 1682, 1537, 1531 1352; HRMS (ESI) Calcd for C₁₃H₇ClN₃O₆ [(M-H)⁻]: 336.0029, found 336.0038.

3-Bromo-4-methoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one

(MeO-Br-DNQ). Yellow solid (43 mg, 62%) $R_f = 0.21$ (CH₂Cl₂/hexane = 4/1); mp 155–157 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 3.55 (s, 3H), 4.28 (s, 3H), 8.75 (d, J = 2.4 Hz, 1H), 8.97 (d, J = 2.4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ = 35.9 (CH₃), 62.1 (CH₃), 108.7 (C), 121.4 (C), 122.5 (CH), 122.6 (CH), 135.9 (C), 139.1 (C), 140.8 (C), 160.1 (C), 160.6 (C); IR: v (cm⁻¹) 1667, 1537, 1531, 1358; HRMS (ESI) Calcd for C₁₁H₇BrN₃O₆ [(M-H)]: 355.9524, found 355.9538.

4-Methoxy-1-methyl-3,6,8-trinitroquinolin-2(1H)-one (3). Yellow solid, $R_f = 0.21$ (CH₂Cl₂/hexane = 4/1); m.p. 204–207 °C; ¹H NMR (DMSO- d_6 , 400 MHz) $\delta = 3.43$ (s, 3H), 4.25 (s, 3H), 9.01 (d, J = 2.8 Hz, 1H), 9.13 (d, J = 2.8 Hz, 1H); ¹³C NMR (DMSO- d_6 , 100 MHz) $\delta = 34.8$ (CH₃), 60.4 (CH₃), 118.9 (C), 124.0 (CH), 124.6 (CH), 129.0 (C), 136.1 (C), 138.8 (C), 140.8 (C), 152.7 (C), 156.8 (C); IR: v (cm⁻¹) 1672, 1537, 1531, 1352; HRMS (ESI) Calcd for C₁₁H₉N₄O₈ [(M+H)⁺]: 325.0415, found 325.0401.

(4-Methoxy-1,8-dimethyl-6-nitro-2-oxo-1,2,3,4-

tetrahydroquinolin-3-yl)sodium (6). Yellow powder (423 mg, 1.33 mmol, 79%); mp 214–216 °C (dec.); ¹H NMR (DMSO-*d*_δ, 400 MHz) δ = 2.47 (s, 3H), 3.14 (s, 3H), 3.28 (s, 3H), 5.73 (s, 1H), 8.02 (d, *J* = 2.8 Hz, 1H), 8.06 (d, *J* = 2.8 Hz, 1H); ¹³C NMR (DMSO-*d*_δ, 100 MHz) δ = 21.3 (CH₃), 35.9 (CH₃), 53.8 (CH₃), 74.0 (CH), 107.5 (C), 121.5 (CH), 126.9 (CH), 127.2 (C), 127.9 (C), 140.8 (C), 146.4 (C), 162.6 (C); IR: ν (cm⁻¹) 1634, 1520, 1514, 1337. Satisfactory analytical data were not given despite several attempts.

(4-Methoxy-1-methyl-6-nitro-2-oxo-1,2,3,4-tetrahydroquinolin-3-

yl)sodium (7). Yellow powder (382 mg, 1.26 mmol, 75%); mp 217–220 °C (dec.); ¹H NMR (DMSO- d_6 , 400 MHz) δ = 3.10 (s, 3H), 3.28 (s, 3H), 5.87 (s, 1H), 7.15 (d, J = 9.2 Hz, 1H), 8.17 (dd, J = 2.4, 9.2 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H); ¹³C NMR (DMSO- d_6 , 100 MHz) δ = 29.1 (CH₃), 53.6 (CH₃), 73.7 (CH), 107.6 (C), 113.7 (CH), 123.2 (C), 124.2 (CH), 124.3 (CH), 139.9 (C), 145.5 (C), 159.4 (C); IR: v (cm⁻¹) 1682, 1537, 1520, 1344. Satisfactory analytical data were not given despite several attempts.

3-Chloro-1,8-dimethyl-4-methoxy-6-nitroquinolin-2(1H)-one (8). Yellow powder (53.6 mg, 0.19 mmol, 95%); $R_{\rm f}$ = 0.28 (CH₂Cl₂); mp 185–188 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 2.80 (s, 3H), 3.88 (s, 3H), 4.23 (s, 3H), 8.22 (d, *J* = 2.4 Hz, 1H), 8.66 (d, *J* = 2.4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ = 24.1 (CH₃), 37.9 (CH₃), 61.6 (CH₃), 115.1 (C), 118.0 (CH), 119.6 (C), 126.8 (C), 129.4 (CH), 142.4 (C), 143.3 (C),

159.1 (C), 161.7 (C); IR: v (cm⁻¹) 1659, 1597, 1522, 1341; HRMS (ESI) Calcd for $C_{12}H_{12}CIN_2O_4 [(M+H)^{\dagger}]$: 283.0480, found 283.0482.

2. Chlore 4 methods 1 method 6 mitromula lin 2(11) and

3-Chloro-4-methoxy-1-methyl-6-nitroquinolin-2(1H)-one (9). Yellow powder (39 mg, 0.15 mmol, 73%); $R_f = 0.27$ (CH₂Cl₂); mp 197 $-199 \,^{\circ}$ C; ¹H NMR (CDCl₃, 400 MHz) $\delta = 3.82$ (s, 3H), 4.27 (s, 3H), 7.47 (d, J = 9.6 Hz, 1H), 8.43 (dd, J = 2.4, 9.6 Hz, 1H), 8.83 (d, J = 2.4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) $\delta = 31.3$ (CH₃), 61.7 (CH₃), 115.0 (CH), 115.7 (C), 117.7 (C), 120.2 (CH), 125.8 (CH), 141.6 (C), 142.7 (C), 158.8 (C), 159.9 (C); IR: v (cm⁻¹) 1651, 1537, 1524, 1347; HRMS (ESI) Calcd for C₁₁H₁₀ClN₂O₄ [(M+H)⁺]: 269.0324, found269.0322.

3-Chloro-1-methyl-6-nitro-4-(2,5-dioxopyrrolidino)quinolin-

2(1*H***)-one (11).** Yellow powder (2.7 mg, 0.01 mmol, 4%); $R_{\rm f}$ = 0.48 (CH₂Cl₂/MeOH = 20/1); mp 283–285 °C; ¹H NMR (DMSOd₆, 400 MHz) δ = 2.98–3.19 (m, 4H), 3.83 (s, 3H), 7.92 (d, *J* = 9.2 Hz, 1H), 8.50 (dd, *J* = 2.8, 9.2 Hz, 1H), 8.64 (d, *J* = 2.8 Hz, 1H); ¹³C NMR (DMSO-d₆, 100 MHz) δ = 29.5 (CH₂), 31.8 (CH₃), 116.8 (C), 117.4 (CH), 120.7 (CH), 126.2 (CH), 127.7 (C), 137.4 (C), 141.7 (C), 142.7 (C), 157.0 (C), 175.4 (C); IR: v (cm⁻¹) 1651, 1537, 1520, 1337; HRMS (ESI) Calcd for C₁₄H₁₁ClN₃O₅ [(M+H)⁺]: 336.0382, found 336.0387.

Synthesis of 4-methoxy-1,8-dimethyl-5-nitroquinolin-2(1H)one (13)

To a solution of **12** (25 mg, 0.10 mmol) in MeOH (0.5 mL), was added MeONa (7 mg, 0.13 mmol), and the resultant mixture was stirred at room temperature for 4 h. Then, the solvent was evaporated to afford a mixture as a yellow residue, from which **13** was isolated as a yellow powder by SiO₂ column chromatography (eluted with CH₂Cl₂, 16.8 mg, 0.07 mmol, 72%); $R_{\rm f}$ = 0.10 (CH₂Cl₂); mp 134–136 °C; ¹H NMR (DMSO- d_6 , 400 MHz) δ = 2.73 (s, 3H), 3.76 (s, 3H), 3.94 (s, 3H), 6.76 (d, *J* = 9.6 Hz, 1H), 8.06 (s, 1H), 8.12 (d, *J* = 9.6 Hz, 1H); ¹³C NMR (DMSO- d_6 , 100 MHz) δ = 23.0 (CH₃), 35.7 (CH₃), 63.9 (CH₃), 116.6 (C), 121.8 (CH), 122.2 (C), 130.0 (CH), 133.5 (CH), 135.6 (C), 145.6 (C), 149.4 (C), 162.7 (C); IR: v (cm⁻¹) 1667, 1566, 1556, 1339; HRMS (ESI) Calcd for C₁₂H₁₂N₂O₄Na [(M+Na)⁺]: 271.0689, found 271.0693.

Synthesis of 3-chloro-3,4-dihydro-4-methoxy-1-methyl-6,8dinitroquinolin-2(*1H*)-one (15)

To a solution of **1a** (100 mg, 0.29 mmol) in CH₂Cl₂ (2.0 mL), was added NCS (46 mg, 0.34 mmol), and the resultant mixture was stirred at room temperature for 0.5 h. Then, the solvent was evaporated to afford a mixture as a yellow residue, from which **15** was isolated as a yellow powder by silica gel column chromatography (eluted with CH₂Cl₂/hexane = 2/1, 46.4 mg, 0.13 mmol, 45%); $R_f = 0.15$ (CH₂Cl₂/hexane = 2/1); mp 158–160 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 3.32 (s, 3H), 3.89 (s, 3H), 4.97 (s, H), 8.47 (d, J = 2.4 Hz, 1H), 8.68 (d, J = 2.4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ = 36.0 (CH₃), 62.4 (CH₃), 81.6 (CH), 97.9 (C), 122.5 (CH), 124.6 (CH), 128.4 (C), 137.2 (C), 139.6 (C), 143.3 (C), 158.3 (C); IR: v (cm⁻¹) 1682, 1573, 1537, 1344; HRMS (ESI) Calcd for C₁₁H₁₀CIN₄O₈ [(M+H)⁺]: 361.0182, found 361.0186.

Synthesis of 2,5-dioxopyrrolidino substituted MeQone 2

To a solution of **TNQ** (70 mg, 0.24 mmol) in MeCN (0.5 ml), was added NCS (38 mg, 0.29 mmol) and Na-SI (29 mg, 0.24 mmol), and the resultant mixture was stirred at room temperature for 6 h. Then, the solvent was evaporated to afford a reaction mixture as a

Journal Name ARTICLE

yellow residue, from which **2** was isolated through SiO₂ column chromatography (eluted with CH₂Cl₂) as a yellow solid (59 mg, 0.15 mmol, 65%). $R_{\rm f}$ = 0.10 (CH₂Cl₂); mp 294–297 °C; ¹H NMR (DMSO- d_6 , 400 MHz) δ = 3.05–3.23 (m, 4H), 3.52 (s, 3H), 8.98 (d, J = 2.4 Hz, 1H), 9.04 (d, J = 2.4 Hz, 1H); ¹³C NMR (DMSO- d_6 , 100 MHz) δ = 29.6 (CH₂), 36.4 (CH₃), 120.2 (C), 123.4 (CH), 124.1 (CH), 128.9 (C), 135.5 (C), 137.3 (C), 139.0 (C), 141.3 (C), 157.8 (C), 175.3 (C); IR: v (cm⁻¹) 1682, 1537, 1531, 1385, 1336; HRMS (ESI) Calcd for C₁₄H₁₀ClN₄O₇ [(M+H)⁺]: 381.0233, found 381.0238.

Hydrazinolysis of 2

To a solution of **2** (50 mg, 0.13 mmol) in MeOH (2.0 mL), NH₂NH₂•H₂O (18 mg, 0.36 mmol) was added, and the resultant mixture was heated at 70 °C for 3 h. Then, the solvent was evaporated to afford a reaction mixture as a yellow solid. After the solid was washed by water (5 mL × 1), NH₂-Cl-DNQ was isolated through filtration as a yellow solid (20 mg, 0.07 mmol, 51%); $R_{\rm f}$ = 0.36 (CH₂Cl₂/MeOH = 10/1); mp > 300 °C; ¹H NMR (DMSO- d_6 , 400 MHz) δ = 3.29 (s, 3H), 7.54 (br s, 2H), 8.89 (d, *J* = 2.0 Hz, 1H); ¹³C NMR (DMSO- d_6 , 400 MHz) δ = 35.1 (CH₃), 99.8 (C), 117.2 (C), 122.5 (CH), 123.2 (CH), 136.5 (C), 138.5 (C), 139.7 (C), 147.1 (C), 158.2 (C); IR: v (cm⁻¹) 1651, 1537, 1531, 1331, 1300; HRMS (ESI) Calcd for C₁₀H₈ClN₄O₅ [(M+H)⁺]: m/z=299.0178, found m/z= 299.0172.

Suzuki-Miyaura coupling reaction of MeO-CI-DNQ

To a solution of MeO-Cl-DNQ (60 mg, 0.19 mmol) in 1,4-dioxane (1.0 mL), were added p-MeC₆H₄B(OH)₂ (39 mg, 0.29 mmol), Pd(PPh₃)₂Cl₂ (14 mg, 0.02 mmol) and Cs₂CO₃ (94 mg, 0.29 mmol), and the resultant mixture was heated at 100 °C for 1 d. Then, the solvent was evaporated to afford a reaction mixture as a yellow residue, from which arylated product 16 was isolated by SiO₂ column chromatography (eluted with CH_2Cl_2 /hexane = 4/1) as a yellow solid (38 mg, 0.10 mmol, 54%); R_f = 0.22 (CH₂Cl₂/hexane = 4/1); mp 172–175 °C; ¹H NMR (CDCl₃, 400 MHz) δ = 2.42 (s, 3H), 3.49 (s, 3H), 3.59 (s, 3H), 7.29 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 8.71 (d, J = 2.4 Hz, 1H), 9.05 (d, J = 2.4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ = 21.4 (CH₃), 35.0 (CH₃), 61.5 (CH₃), 119.9 (C), 121.9 (CH), 122.0 (C), 123.2 (CH), 128.4 (C), 129.2 (CH), 130.4 (CH), 136.5 (C), 138.5 (C), 139.0 (C), 140.3 (C), 158.2 (C), 163.8 (C); IR: v (cm⁻¹) 1667, 1537, 1531, 1360, 1332; HRMS (ESI) Calcd for $C_{18}H_{16}N_3O_6$ [(M+H)⁺]: 370.1034, found 370.1037.

Notes and references

- S. Singh, T. Das, M. Awasthi, V. P. Pandey, B. Pandey and U. N. Dwivedi, *Biotechnol. Appl. Biochem.*, DOI: 10.1002/bab.1346;
 K. Nakashima, M. Oyama, T. Ito, Y. Akao, J. R. Witono, D. Darnaedi, T. Tanaka, J. Murata and M. Linuma, *Tetrahedron*, 2012, **68**, 2421; F. O'Donell, T. J. P. Smyth, V. N. Ramachandran and W. F. Smyth, *Int. J. Antimicrob. Agents*, 2010, **35**, 30; J. P. Michael, *Nat. Prod. Rep.*, 2008, **25**, 166; J. P. Michael, *Nat. Prod. Rep.*, 2007, **24**, 223; C. Ito, *J. Nat. Prod.*, 2004, **67**, 1488; M. F. Grundon, *The Alkaloids: Quinoline Alkaloids Related to Anthranic Acid*, Academic Press: London, 1968, 32, 341.
- Recent papers: K. H. Vardhan Reddy, J.-D. Brion, S. Messaoudi and M. Alami, *J. Org. Chem.*, 2016, **81**, 424; B. Reichart, G. Guedes de la Cruz, K. Zangger, C. O. Kappe and T. Glasnov, *Adv. Synth. Cat.*, 2016, **358**, 50; U. Dutta, A. Deb, D. W. Lupton and D. Maiti, *Chem. Commun.*, 2015, **51**, 17744;

M. Feng, B. Tang, N. Wang, H.-X. Xu and X. Jiang, Angew. Chem. Int. Ed., 2015, **54**, 14960; A. Faust, T. Voeller, F. Busch, M. Schaefers, J. Roth, S. Hermann and T. Vogl, Chem. Commun., 2015, **51**, 15637; M. Pieta, J. Kedzia, A. Janecka, D. K. Pomorska, M. Rozalski, U. Krajewska and T. Janecki, *RSC* Adv. 2015, **5**, 78324; W.-P. Mai, J.-T. Wang, Y.-M. Xiao, P. Mao and K. Lu, Tetrahedron, 2015, **71**, 8041.

- 3 Recent papers: Y.-Q. Du, H. Liu, C.-J. Li, J.-Z. Yang, J. Ma, D. Zhang and D.-M. Zhang, J. Asian Nat. Prod. Res., 2015, 17, 1048; P. K. Patel, R. V. Patel, D. H. Mahajan, P. A. Parikh, G. N. Mehta, C. Pannecouque, E. De Clercq and K. H. Chikhalia, J. Heterocycl. Chem., 2014, 51, 1641; M. A. Ibrahim, H. M. Hassanin and Y. A. Alnamer, Synth. Commun., 2014, 44, 3470.
- 4 Severe reaction conditions are usually required for chemical conversion of **MeQones** presumably due to the aromaticity: H. Görner and T. Wolff, *Photochem. Photobiol.*, 2008, **84**, 1224; R. Fujita, T. Yoshisuji, S. Wakayanagi, H. Wakamatsu and H. Matsuzaki, *Chem. Pharm. Bull.*, 2006, **54**, 204; J. Hashim, T. N. Glasnov, J. M. Kremsner and C. O. Kappe, *J. Org. Chem.*, 2006, **71**, 1707.
- 5 V. Nadaraj, S. T. Selvi and R. Sasi, *ARKIVOC*, 2006 (x), 82; D. L. Boger, S. R. Duff, J. S. Panek and M. Yasuda, *J. Org. Chem.*, 1985, **50**, 5790.
- 6 G. Bratulescu, *Lett. Org. Chem.*, 2008, **5**, 133; K. Jansson, T. Fristedt, A. Olsson, B. Svensson and S. Jönsson, *J. Org. Chem.*, 2006, **71**, 1658.
- 7 A. B. Ahvale, H. Prokopcová, J. Šefčovičová, W. Steinschifter, A. E. Täubl, G. Uray and W. Stadlbauer, *Eur. J. Org. Chem.*, 2008, 563; H. Sheibani, M. H. Mosslemin, S. Behzadi, M. R. Islami and K. Saide, *Synthesis*, 2006, 435.
- N. Nishiwaki, *Molecules*, 2010, **15**, 5174; M. Asahara, M. Ohtsutsumi, M. Ariga and N. Nishiwaki, *Heterocycles*, 2009, **78**, 2851; M. Asahara, M. Ohtsutsumi, M. Tamura, N. Nishiwaki and M. Ariga, *Bull. Chem. Soc. Jpn.*, 2005, **78**, 2235; M. Asahara, C. Shibano, K. Koyama, M. Tamura, Y. Tohda, N. Nishiwaki and M. Ariga, *Tetrahedron Letters*, 2005, **46**, 7519.
- 9 X. Chen, K. Kobiro, H. Asahara, K. Kakiuchi, R. Sugimoto, K. Saigo and N. Nishiwaki, *Tetrahedron*, 2013, **69**, 4624; N. Nishiwaki, C. Tanaka, M. Asahara, N. Asaka, Y. Tohda and M. Ariga, *Heterocycles*, 1999, **51**, 567.
- N. Nishiwaki, M. Sakashita, M. Azuma, C. Tanaka, M. Tamura, N. Asahara, K. Hori, Y. Tohda and M. Ariga, *Tetrahedron*, 2002, **58**, 473.
- 11 M. Asahara, M. Nagamatsu, Y. Tohda, N. Nishiwaki and M. Ariga, *ARKIVOC*, 2005 (i), 1.
- 12 J. Axford, N. Dales and M. J. Sung, U.S. Pat. Appl. Publ. 2014 0206661.
- 13 S. L. Clarke and G. P. McGlacken, *Tetrahedron*, 2015, **71**, 2906.
- 14 A. Klasek, O. Rudolf, M. Rouchal, A. Lycka and A. Ruzicka, *Tetrahedron*, 2013, **69**, 492.
- 15 Z. Wang, L. Xue, Y. He, L. Weng and L. Fang, J. Org. Chem., 2014, **79**, 9628; Z. Wang and J. Wu, *Tetrahedron*, 2008, **64**, 1736.
- 16 D. Audisio, S. Messaoudi, L. Cegielkowski, J.-F. Peyrat, J.-D. Brion, D. Methy-Gonnot, C. Radanyi, J.-M. Renoir and M. Alami, *ChemMedChem*, 2011, 6, 804.
- 17 S. A. Barr, C. F. Neville, M. F. Grundon, D. R. Boyd, J. F. Malone and T. A. Evans, *J. Chem. Soc., Perkin Trans.* 1, 1995, 445.
- 18 G. Bartoli, M. Bosco, E. Foresti and G. Pardella, J. Org. Chem., 1981, 46, 3109.
- C. D. Haffner, J. D. Becherer, E. E. Boros, R. Cadilla, T. Carpenter, D. Cowan, D. N. Deaton, Y. Guo, W. Harrington, B. R. Henke, M. R. Jeune, I. Kaldor, N. Milliken, K. G. Petrov, F. Preugschat, C. Schulte, B. G. Shearer, T. Shearer, T. L. Smalley Jr., E. L. Stewart, J. D. Stuart and J. C. Ulrich, *J. Med. Chem.*, 2015, **58**, 3548; Pudlo, V. Luzet, L. Ismaili, I. Tomassoli, A.

ARTICLE

lutzeler and B. Refouvelet, *Bioorg. Med. Chem.*, 2014, **22**, 2496; I. V. Ukrainets, L. V. Sidorenko and O. V. Gorokhova, *Chem. Heterocycl. Compd.*, 2005, **41**, 1151.

- 20 B. Reichart, G. Guedes de la Cruz, K. Zangger, C. O. Kappe and T. Glasnov, *Adv. Synth. Cat.*, 2016, **358**, 50; J. Bergman, A. Brynolf and E. Vuorinen, *Tetrahedron*, 1986, **42**, 3689.
- Z. Wang, R. Fan and J. Wu, Adv. Synth. Cat., 2007, 349, 1943;
 J. Wu, L. Zhang and X. Sun, Chem. Lett., 2005, 34, 550.
- 22 T. Okuzumi, K. Sagi, T. Yoshimura, Y. Tanaka, E. Nakanishi, M. Ono and M. Murata, PCT Int. Appl. WO 2003 053926.
- 23 N. Nishiwaki, A. Tanaka, M. Uchida, Y. Tohda and M. Ariga, Bull. Chem. Soc. Jpn., 1996, **69**, 1337.

Page 8 of 8